Clotrimazole
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Clotrimazole: From Fungal Infections to Acne (Disease)
One-Sentence Summary
Clotrimazole is a broad-spectrum topical antimycotic (imidazole/azole class) with established efficacy against Candida and dermatophyte infections such as vulvovaginal candidiasis and tinea pedis. The TxGNN model’s top-ranked prediction for this drug is Acne (Disease), but this direction is currently supported by only 1 clinical trial (suspended, combination product) and no published literature, and the pack’s own mechanistic review flags the biological rationale as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in India (0 licenses); internationally documented as a topical antifungal for candidiasis and dermatophyte infections (per literature, PMID 24863842) |
| Predicted New Indication | Acne (Disease) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for clotrimazole is currently a data gap in this pack. Based on known pharmacology and the literature retrieved (PMID 24863842), clotrimazole is a synthetic imidazole antimycotic that inhibits fungal ergosterol biosynthesis, and its efficacy in Candida-related infections (vulvovaginal candidiasis, oropharyngeal candidiasis) and dermatophytoses (tinea pedis) is well established.
The link to acne, however, is mechanistically weak. Acne vulgaris is driven primarily by Cutibacterium acnes proliferation, excess sebum production, and follicular hyperkeratinization — none of which correspond to clotrimazole’s antifungal mode of action. The pack’s own repurposing rationale notes that an antifungal mechanism could only be relevant in the narrow, atypical differential diagnosis of Malassezia folliculitis (“pityrosporum folliculitis,” sometimes clinically mistaken for acne), not in typical acne vulgaris. This makes the prediction a plausible but stretched mechanistic extension rather than a direct therapeutic match.
The single supporting trial (a suspended Phase 2/3 study of a three-drug combination cream) cannot isolate clotrimazole’s contribution, and no literature evidence was retrieved for this indication pairing — consistent with the model’s own L4 / Hold designation.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Evaluated comparative efficacy of a triple combination (beclometasone 0.025% + gentamicin 0.1% + clotrimazole 1% topical cream) in patients with contaminated/infected dermatosis with bilateral symmetrical lesions; clotrimazole was only one component of a fixed combination, and the trial did not complete. |
Literature Evidence
Currently no related literature available.
Safety Considerations
- Drug Interactions: DDI screening returned 481 total interactions on record. Notable Major-level interactions include Fentanyl, Alfentanil, Amiodarone, and Hydrocodone. Multiple Moderate-level interactions are also documented, including Abemaciclib, Paclitaxel, Acalabrutinib, Nifedipine, Levonorgestrel, Estradiol, Alprazolam, Apixaban, and Aprepitant, among others. Given the scale of the interaction list, a full DDI review against the target patient’s concomitant medications is warranted before any clinical use.
Key warnings and contraindications from the local product label are not currently available in this pack (blocking data gap — see below).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Acne) has only L4-level evidence — a single suspended, non-isolating combination trial and no literature — and the pack’s own mechanistic analysis rates the biological link as weak. Combined with the missing TFDA-equivalent label data (blocking gap) and clotrimazole’s unregistered status in India, this candidate does not currently support progression beyond Hold.
To proceed, the following is needed:
- Local product label / package insert data (warnings, contraindications) — currently a Blocking data gap
- Confirmed mechanism of action documentation from DrugBank or equivalent
- If pursued, reclassification of the target population toward Malassezia (pityrosporum) folliculitis rather than acne vulgaris, to align the indication with the drug’s actual antifungal mechanism
Note for evidence triage: the pack also contains two lower-ranked but substantially better-evidenced predictions for this drug — vulvovaginitis (22 clinical trials including multiple completed Phase 3/4 RCTs, 20 literature citations, and an evidence profile consistent with clotrimazole’s already-established antifungal use) and postmenopausal atrophic vaginitis (weaker, L4/Hold, similar caveats to acne). Given the strength of the vulvovaginitis evidence, it may warrant separate evaluation as the more actionable repurposing candidate for this drug, despite its lower TxGNN rank.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.